UroGen Pharma Ltd.
ZUSDURI
recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)
Resolved
187days ago
Approval decision · Jan 1, 2026
What's at stake
A final FDA approval decision on ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is expected Jan 1, 2026.
Primary source
· SEC 8-K
verified 17h ago
“The permanent Healthcare Common Procedure Coding System Level II J Code (J9282) became effective on January 1, 2026 and has enabled broader adoption by improving reimbursement clarity and confidence across both hospital and community settin”